CoChat
Sign Up
Cited by 662

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

De-novo and acquired resistance to immune checkpoint targeting

Syn, Nicholas L, Teng, Michele W L, Mok, Tony S K, Soo, Ross A·2017·The Lancet Oncology
DOI 10.1016/s1470-2045(17)30607-1
Open this paper in CoChat — free account

Abstract

Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to evade T-cell-mediated immunosurveillance. Cancer genomes bear signatures of clonal evolution and selection, particularly implicating acquired defects in interferon receptor signalling and antigen presentation. In this Review, we discuss the biological processes that operate in the formation of so-called immunoresistant niches, and describe the latest progress in the development of combination strategies to reinstate immunosurveillance in immune-refractory tumours.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30607-1

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 76

  1. Ehrlich, 1909, Über den jetzigen stand der karzinomforschung, Ned Tijdschr Geneeskd, 5, 273
  2. Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 · DOI · Paper page
  3. Eggermont, 2015, Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 522, 10.1016/S1470-2045(15)70122-1 · DOI · Paper page
  4. Eggermont, 2016, Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy, N Engl J Med, 375, 1845, 10.1056/NEJMoa1611299 · DOI
  5. Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  6. Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 · DOI
  7. Armand, 2016, Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure, J Clin Oncol, 34, 3733, 10.1200/JCO.2016.67.3467 · DOI
  8. Fanale, 2017, Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 CHECKMATE 205 trial, Hematol Oncol, 35, 135, 10.1002/hon.2437_124 · DOI
  9. Chen, 2017, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J Clin Oncol, 35, 2125, 10.1200/JCO.2016.72.1316 · DOI
  10. Sharma, 2016, Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial, Lancet Oncol, 17, 1590, 10.1016/S1470-2045(16)30496-X · DOI
  11. Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 · DOI · Paper page
  12. Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, 18, 312, 10.1016/S1470-2045(17)30065-7 · DOI
  13. Powles, 2017, Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma, J Clin Oncol, 35, 10.1200/JCO.2017.35.6_suppl.286 · DOI
  14. Bauml, 2017, Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study, J Clin Oncol, 35, 1542, 10.1200/JCO.2016.70.1524 · DOI
  15. Harrington, 2017, Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial, Lancet Oncol, 18, 1104, 10.1016/S1470-2045(17)30421-7 · DOI
  16. Kaufman, 2016, Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial, Lancet Oncol, 17, 1374, 10.1016/S1470-2045(16)30364-3 · DOI · Paper page
  17. Schellens, 2017, Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study, Proc Am Soc Clin Oncol, 35, 5514, 10.1200/JCO.2017.35.15_suppl.5514 · DOI
  18. Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, 18, 623, 10.1016/S1470-2045(17)30169-9 · DOI
  19. Le, 2016, KEYNOTE-164: phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma, Proc Am Soc Clin Oncol, 34
  20. Diaz, 2017, KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma, Proc Am Soc Clin Oncol, 34
  21. Giannakis, 2016, Genomic correlates of immune-cell infiltrates in colorectal carcinoma, Cell Rep, 15, 857, 10.1016/j.celrep.2016.03.075 · DOI
  22. Pereira, 2016, Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition, Clin Cancer Res, 23, 3203, 10.1158/1078-0432.CCR-16-1946 · DOI
  23. Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958 · DOI · Paper page
  24. Zhao, 2016, Melanoma lesions independently acquire T-cell resistance during metastatic latency, Cancer Res, 76, 4347, 10.1158/0008-5472.CAN-16-0008 · DOI
  25. Wang, 2017, Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy, Cancer Res, 77, 839, 10.1158/0008-5472.CAN-15-3142 · DOI
  26. Syn, 2017, Mutational features associated with immunoreactivity in non-small cell lung cancer, J Thorac Oncol, 12, S821, 10.1016/j.jtho.2016.11.1110 · DOI
  27. Roh, 2017, Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance, Sci Transl Med, 9, eaah3560, 10.1126/scitranslmed.aah3560 · DOI · Paper page
  28. Spiotto, 2004, Bystander elimination of antigen loss variants in established tumors, Nat Med, 10, 294, 10.1038/nm999 · DOI
  29. Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 · DOI · Paper page
  30. Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755 · DOI
  31. Verdegaal, 2016, Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature, 536, 91, 10.1038/nature18945 · DOI
  32. Anagnostou, 2017, Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discov, 7, 264, 10.1158/2159-8290.CD-16-0828 · DOI
  33. Takeda, 2017, IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting, Nat Commun, 8, 14607, 10.1038/ncomms14607 · DOI
  34. Goff, 2016, Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma, J Clin Oncol, 34, 2389, 10.1200/JCO.2016.66.7220 · DOI
  35. Spranger, 2016, Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma, Proc Natl Acad Sci, 113, E7759, 10.1073/pnas.1609376113 · DOI
  36. Shin, 2017, Primary resistance to PD-1 blockade mediated by JAK1/2 mutations, Cancer Discov, 7, 188, 10.1158/2159-8290.CD-16-1223 · DOI · Paper page
  37. Fu, 2015, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci Transl Med, 7, 283ra52, 10.1126/scitranslmed.aaa4306 · DOI · Paper page
  38. Stojdl, 2000, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, Nat Med, 6, 821, 10.1038/77558 · DOI
  39. Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J Clin Oncol, 33, 2780, 10.1200/JCO.2014.58.3377 · DOI
  40. Ngiow, 2016, Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor, Cancer Res, 76, 6266, 10.1158/0008-5472.CAN-16-2141 · DOI
  41. Mognol, 2017, Exhaustion-associated regulatory regions in CD8 + tumor-infiltrating T cells, Proc Natl Acad Sci, 114, E2776, 10.1073/pnas.1620498114 · DOI
  42. Huang, 2017, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, 545, 60, 10.1038/nature22079 · DOI · Paper page
  43. Kakavand, 2015, PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients, Clin Cancer Res, 21, 3140, 10.1158/1078-0432.CCR-14-2023 · DOI
  44. Pfirschke, 2016, Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy, Immunity, 44, 343, 10.1016/j.immuni.2015.11.024 · DOI
  45. Johnson, 2017, ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma, Proc Am Soc Clin Oncol, 35, 9529, 10.1200/JCO.2017.35.15_suppl.9529 · DOI
  46. Lu, 2017, Effective combinatorial immunotherapy for castration-resistant prostate cancer, Nature, 543, 728, 10.1038/nature21676 · DOI
  47. De Henau, 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells, Nature, 539, 443, 10.1038/nature20554 · DOI
  48. Zelenay, 2015, Cyclooxygenase-dependent tumor growth through evasion of immunity, Cell, 162, 1257, 10.1016/j.cell.2015.08.015 · DOI
  49. Delgoffe, 2016, Filling the tank: keeping antitumor T cells metabolically fit for the long haul, Cancer Immunol Res, 4, 1001, 10.1158/2326-6066.CIR-16-0244 · DOI
  50. Brand, 2016, LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells, Cell Metab, 24, 657, 10.1016/j.cmet.2016.08.011 · DOI · Paper page
  51. Young, 2014, Targeting cancer-derived adenosine: new therapeutic approaches, Cancer Discov, 4, 879, 10.1158/2159-8290.CD-14-0341 · DOI
  52. Fischer, 2007, Inhibitory effect of tumor cell-derived lactic acid on human T cells, Blood, 109, 3812, 10.1182/blood-2006-07-035972 · DOI · Paper page
  53. Diem, 2016, Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma, Br J Cancer, 114, 256, 10.1038/bjc.2015.467 · DOI · Paper page
  54. Zimmer, 2017, Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma, Eur J Cancer, 75, 47, 10.1016/j.ejca.2017.01.009 · DOI
  55. Gangadhar, 2016, Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202/KEYNOTE-037, Ann Oncol, 27, vi379
  56. Peng, 2016, Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, 6, 202, 10.1158/2159-8290.CD-15-0283 · DOI · Paper page
  57. George, 2017, Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma, Immunity, 46, 197, 10.1016/j.immuni.2017.02.001 · DOI
  58. Chen, 2016, Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, Cancer Discov, 6, 827, 10.1158/2159-8290.CD-15-1545 · DOI · Paper page
  59. Motz, 2014, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors, Nat Med, 20, 607, 10.1038/nm.3541 · DOI
  60. Lee, 2017, J Clin Oncol, 35, 2193, 10.1200/JCO.2016.72.1340 · DOI
  61. Wallin, 2016, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, Nat Commun, 7, 12624, 10.1038/ncomms12624 · DOI
  62. Falletta, 2017, Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, 31, 18, 10.1101/gad.290940.116 · DOI
  63. Landsberg, 2012, Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, Nature, 490, 412, 10.1038/nature11538 · DOI
  64. Bertrand, 2015, Blocking tumor necrosis factor α enhances CD8 T-cell-dependent immunity in experimental melanoma, Cancer Res, 75, 2619, 10.1158/0008-5472.CAN-14-2524 · DOI · Paper page
  65. Santisteban, 2009, Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells, Cancer Res, 69, 2887, 10.1158/0008-5472.CAN-08-3343 · DOI
  66. Lou, 2016, Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma, Clin Cancer Res, 22, 3630, 10.1158/1078-0432.CCR-15-1434 · DOI
  67. Derosa, 2017, Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors, Proc Am Soc Clin Oncol, 35, 462, 10.1200/JCO.2017.35.6_suppl.462 · DOI
  68. Vancheswaran, 2017, Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma, Proc Am Soc Clin Oncol, 35, 2, 10.1200/JCO.2017.35.7_suppl.2 · DOI
  69. Zitvogel, 2016, Microbiome and anticancer immunosurveillance, Cell, 165, 276, 10.1016/j.cell.2016.03.001 · DOI · Paper page
  70. Shayan, 2017, Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer, Oncoimmunology, 6, e1261779, 10.1080/2162402X.2016.1261779 · DOI
  71. Huang, 2016, Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer, Oncoimmunology, 6, e1249561, 10.1080/2162402X.2016.1249561 · DOI
  72. Gao, 2017, VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer, Nat Med, 23, 551, 10.1038/nm.4308 · DOI · Paper page
  73. Champiat, 2017, Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin Cancer Res, 23, 1920, 10.1158/1078-0432.CCR-16-1741 · DOI
  74. Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689 · DOI · Paper page
  75. Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin Cancer Res, 19, 1021, 10.1158/1078-0432.CCR-12-2063 · DOI
  76. Teng, 2015, Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res, 75, 2139, 10.1158/0008-5472.CAN-15-0255 · DOI

Cited by

Sorted by citations

See all 662

Metadata

Authors
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2017-12
Volume
18
Issue
12
Pages
e731-e741
ISSN
1470-2045
DOI
10.1016/s1470-2045(17)30607-1
Cited by
662
References
35
Language
en
Licence
Funders
  • AstraZeneca
  • National Health and Medical Research Council
  • National Medical Research Council (NMRC/CG/012/2013)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review